Xencor Announces Change to Board of Directors Read more about Xencor Announces Change to Board of Directors
National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology Read more about National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology
Xencor to Present at Two Upcoming Conferences in December Read more about Xencor to Present at Two Upcoming Conferences in December
Xencor Presents Data on XmAb5871 Program at American College of Rheumatology (ACR) 2015 Annual Meeting Read more about Xencor Presents Data on XmAb5871 Program at American College of Rheumatology (ACR) 2015 Annual Meeting
Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting Read more about Preclinical Data of Xencor's XmAb Bispecific Technology to be Presented at Upcoming ASH Annual Meeting
Xencor to Present at Credit Suisse 24th Annual Healthcare Conference Read more about Xencor to Present at Credit Suisse 24th Annual Healthcare Conference
Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update Read more about Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update
Xencor to Host Third Quarter 2015 Financial Results Webcast and Conference Call on November 3, 2015 Read more about Xencor to Host Third Quarter 2015 Financial Results Webcast and Conference Call on November 3, 2015
Xencor to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable Read more about Xencor to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable
Xencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb® Cytotoxic Fc Domain Read more about Xencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb® Cytotoxic Fc Domain
